GVBLBiotechnology
Genomic Valley Biotech Ltd — PE Ratio & Valuation Analysis
₹28.00
+3.74%
Current P/E88.14xPrice to earnings
Industry P/E51.82xSector average
4Y Avg P/E810.0x89.1% below avg
⚠️
70.1% Premium to Industry
GVBL P/E 88.14x vs sector avg 51.82x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹1.17 | ₹25 | 21.1x |
| 2024 | ₹0.05 | ₹80 | 1599x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Genomic Valley Biotech Ltd Valuation
Genomic Valley Biotech Ltd (GVBL) currently trades at 88.14x earnings. The Biotechnology sector average PE is 51.82x. GVBL commands a premium, reflecting high growth expectations. Historically, GVBL has traded at an average PE of 810.0x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
9.68%
Dividend Yield
0.00%
More on Genomic Valley Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.